J
Jonathan E. Zuckerman
Researcher at University of California, Los Angeles
Publications - 68
Citations - 5516
Jonathan E. Zuckerman is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Acute kidney injury. The author has an hindex of 17, co-authored 58 publications receiving 4504 citations. Previous affiliations of Jonathan E. Zuckerman include UCLA Medical Center & California Institute of Technology.
Papers
More filters
Journal ArticleDOI
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis,Jonathan E. Zuckerman,Chung Hang Jonathan Choi,David Seligson,Anthony W. Tolcher,Christopher A. Alabi,Christopher A. Alabi,Yun Yen,Jeremy D. Heidel,Antoni Ribas +9 more
TL;DR: Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.
Journal ArticleDOI
Targeting kidney mesangium by nanoparticles of defined size.
TL;DR: These data show that nanoparticles of ~75 ± 25-nm diameters target the mesangium of the kidney, and establish design criteria for constructing nanoparticle-based therapeutics for targeting diseases that involve the mesANGium ofThe kidney.
Journal ArticleDOI
Virtual histological staining of unlabelled tissue-autofluorescence images via deep learning.
Yair Rivenson,Hongda Wang,Zhensong Wei,Kevin de Haan,Yibo Zhang,Yichen Wu,Harun Gunaydin,Jonathan E. Zuckerman,Thomas Chong,Anthony Sisk,Lindsey M Westbrook,W. Dean Wallace,Aydogan Ozcan +12 more
TL;DR: It is shown that a convolutional neural network trained using a generative adversarial-network model can transform wide-field autofluorescence images of unlabelled tissue sections into images that are equivalent to the bright-field images of histologically stained versions of the same samples.
Journal ArticleDOI
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
TL;DR: This Review critically assesses a small number of Phase I clinical trials involving patients with solid tumours and discusses their implications for future clinical trial design.
Journal ArticleDOI
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
TL;DR: It is shown that a component of the renal filtration barrier—the glomerular basement membrane (GBM)—can disassemble cationic cyclodextrin-containing polymer (CDP)-based siRNA nanoparticles and, thereby, facilitate their rapid elimination from circulation.